Correlation Between Coronary and Carotid Atherosclerotic Disease and Links With Clinical Outcomes

Completed

• Conditions: Vascular Disease

• Registration Number: NCT02114541
• Lead Sponsor: Montreal Heart Institute

Brief Summary

The relationship of the natural history of atherosclerosis between different vascular beds has not been well characterized. Determination and comparison of the relative rates of progression and extents of atherosclerosis in the coronary and carotid arterial trees may have major impacts on clinical research and clinical practice. Correlation between findings in the carotid and coronary circulations is an important scientific and clinical topic to address. Results from a well design study incorporating imaging technologies that currently represent the gold standards for the assessment of coronary and carotid artery plaque burden, will have potentially impact on clinical research and clinical practice.

Detailed Description

The CAIN-003 study was a prospective observational multi-center imaging study of subjects scheduled for clinically-indicated coronary angiography. CAIN-003 provided for the collection of baseline coronary angiography and IVUS imaging data along with baseline carotid ultrasound imaging. CAIN-003 study participants underwent follow-up coronary and carotid imaging at 2-years, and were then contacted by phone on an annual basis for an additional 3 years for the collection of cardiovascular and cerebrovascular clinical endpoints.

MHICC-31052012 was a prospective, observational, multi-center study of subjects who had successfully undergone baseline imaging in the dal-PLAQUE 2 study (A multicenter, double-blind, randomized, placebo-controlled study, evaluating the effect of treatment with dalcetrapib 600 mg on atherosclerosis disease). The dal-PLAQUE 2 study, which provided for the collection of baseline and 2-year follow-up coronary angiography, coronary IVUS and carotid ultrasound imaging data, was terminated by the sponsor prior to completion due to the discontinuation of the dalcetrapib drug development program. The MHICC-31052012 study allowed for the collection of follow-up imaging and clinical endpoint data from subjects who had successfully undergone baseline IVUS imaging in dal-PLAQUE 2.

Data from CAIN-003 and MHICC-31052012 was pooled to support the objective of determining the correlation and clinical relevance of these imaging endpoints.

The objectives of the CAIN-003 and MHICC-31052012 study were:

* To compare the extent of atherosclerosis present in the coronary vasculature with the extent of atherosclerosis present in the carotid vasculature at a single point in time.

* To compare the associations of atherosclerosis burden with coronary risk factors in the coronary arteries and carotid arteries, in multivariable regression.

* To compare the rate of atherosclerosis progression or regression in the coronary vasculature with the rate of atherosclerosis progression or regression in the carotid vasculature over a 2-year period.

* To determine the correlation between imaging biomarkers and cardiovascular outcomes over a 5-year period.

Study Timeline

• Study Start: 2010-02-03
• Study First Submitted: 2013-07-18
• Study First Submitted QC: 2014-04-13
• Study First Posted: 2014-04-15
• Primary Completion: 2017-12-12
• Study Completion: 2017-12-12
• Status Verified: 2022-02
• Last Update Submitted: 2022-02-22
• Last Update Posted: 2022-03-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1339

Inclusion Criteria

1. Male and female patients over the age of 18 years.

2. Patients scheduled for clinically indicated coronary angiography and possible ad hoc percutaneous coronary intervention (PCI) will be evaluated before their scheduled procedure.

3. Written informed consent (approved by the Institutional Review Board [IRB]/Independent Ethics Committee [IEC]) obtained prior to any study specific procedures.

4. Patients considered to be stable at enrollment (at the discretion of the investigator) are eligible provided they meet all other entry criteria.

5. Angiographic inclusion criteria:

   • Entire Coronary Circulation: The patient must have angiographic evidence of coronary artery disease as defined by at least one lesion in any of the three major native coronary arteries that has >20% reduction in lumen diameter by angiographic visual estimation or prior history of PCI. This vessel does not need to be the target coronary artery for IVUS. Any vessel with previous PCI may not be used as the target coronary artery.
   • Left Main Coronary Artery: The patient must not have > 50% reduction in lumen diameter by visual angiographic estimation.
   • Target Coronary Artery: Patient will be required to have one "target" coronary artery for IVUS that has not undergone prior PCI, that is not a candidate to undergo PCI presently or in the next 24 months, and that has not been the cause of a recent myocardial infarction. The proximal 4 cm of the "target" artery in which

IVUS examination will be performed at baseline:

• Must have a diameter stenosis < 50% lumen diameter by visual assessment of the angiogram;
• Must have a reference diameter > 2.5 mm;
• Must be free of filling defects suggestive of thrombus;
• Must not present any anatomical characteristic (such as but not limited to severe tortuosity or calcification) that would impede IVUS interrogation at baseline or follow-up
• Note: a lesion of up to 60% stenosis is permitted, distal to the target segment. A side branch of the target coronary artery for IVUS may not be a target for PCI.

Exclusion Criteria

Subjects presenting with any of the following will not be included in the study:

1. Women of childbearing potential (women who are not surgically sterile or postmenopausal defined as amenorrhea for >12 months) who refuse to undergo a urine or serum pregnancy test immediately prior to baseline and repeat imaging evaluations The urine or serum pregnancy test must be negative prior to imaging evaluations.
2. Previous coronary artery bypass graft (CABG) surgery or probable need for CABG in the next 24 months.
3. Patients who have symptomatic congestive heart failure (CHF) (New York Heart Association [NYHA] Class III or IV) at baseline.
4. Patients with clinically significant valvular heart disease likely to require surgical repair or replacement during the treatment period of the study
5. Any clinically significant medical condition or presence of any laboratory abnormality that is considered by the investigator to be clinically important and could interfere with the conduct of the study.
6. The presence of severe liver disease as defined by the presence of cirrhosis, chronic active hepatitis, or chronic jaundice with hyperbilirubinemia,
7. Patients with eGFR < 45 ml/min prior to baseline imaging procedures, or with nephrotic syndrome
8. Patients with a life expectancy less than 2 years.
9. History of malignancy (except for curatively treated basal cell or squamous cell carcinoma of the skin) during the 3 years prior to the screening.
10. Unable or unwilling to comply with protocol requirements, or deemed by the investigator to be unfit for the study.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Nominal change at follow-up from baseline in percent atheroma volume (PAV) obtained using intravascular ultrasound (IVUS)	Participants will have a baseline IVUS and a two year follow-up IVUS	This endpoint will be the nominal change at follow-up from baseline in percent atheroma volume computed by dividing plaque volume by external elastic membrane volume and then multiplying by 100 at both time points, baseline and 2 year follow-up.

Secondary Outcome Measures

Name	Time	Method
plaque volume in target coronary artery	change at 2 year follow-up from baseline	This secondary IVUS endpoint will include the nominal change in plaque volume in the target coronary artery, as well as the percent (relative) change in plaque volume.
change in plaque volume in the 5-mm sub-segment of target coronary artery	change at 2 year follow-up from baseline	change in plaque volume in the 5-mm sub-segment with the greatest disease burden at baseline, and change in plaque volume in the 5-mm sub-segment with the smallest plaque area at baseline.
Total vessel volume in the target coronary artery	change at final 2 year follow-up from baseline	Total vessel volume for all anatomically comparable slices in the 30-mm target coronary artery segment and the change in plaque characterization indices.
change in coronary score assessed by quantitative coronary angiography	change at final 2 year follow-up from baseline	Evaluation of change in coronary score assessed by quantitative coronary angiography and defined as the per-patient mean of the minimal lumen diameter for all lesions measured. As well evaluation of the cumulative coronary stenosis score (calculated by adding all percent diameter stenoses in standard international units).
nominal change in carotid IMT(CIMT)	change at final 2 year follow-up from baseline	This secondary endpoint will be obtained using 2D B-mode carotid ultrasound and will be the nominal change at final follow-up from baseline in carotid IMT(CIMT), where CIMT is computed as the per scan average of the mean IMT values of carotid segments.

Trial Locations

Locations (67)

John Hopkins University Office Capitol Region Research-CAPRES; 🇺🇸 Columbia, Maryland, United States

University of southern California; 🇺🇸 Los Angeles, California, United States

Los Angeles Biomedical Research Institute at Harbor; 🇺🇸 Torrance, California, United States

Sarasota Memorial Hospital; 🇺🇸 Sarasota, Florida, United States

Emory University VA Medical Center; 🇺🇸 Decatur, Georgia, United States

The Valley Hospital; 🇺🇸 Ridgewood, New Jersey, United States

Mercy Health Partners; 🇺🇸 Muskegon, Michigan, United States

CV Research at MidMichigan Medical Center Midland; 🇺🇸 Midland, Michigan, United States

University of Toledo Medical Center; 🇺🇸 Toledo, Ohio, United States

Cardiac and Vascular Research Center of Northern Michigan; 🇺🇸 Petoskey, Michigan, United States

Parkway Cardiology associates; 🇺🇸 Oak Ridge, Tennessee, United States

Mazankowski Alberta Heart Institute University Of Alberta Hospital ABACUS; 🇨🇦 Edmonton, Alberta, Canada

Interventional Cardiology Research, St. Paul's Hospital; 🇨🇦 Vancouver, British Columbia, Canada

Eastern Regional Health Authority; 🇨🇦 Saint John's, Newfoundland and Labrador, Canada

Cambridge Cardiac Care; 🇨🇦 Cambridge, Ontario, Canada

McMaster Clinic Hamilton General Hospital; 🇨🇦 Hamilton, Ontario, Canada

KMH Cardiology & Diagnostics Centre; 🇨🇦 Mississauga, Ontario, Canada

Heart Care Research; 🇨🇦 Oshawa, Ontario, Canada

York PCI Research; 🇨🇦 Newmarket, Ontario, Canada

University Hospital/LHSC; 🇨🇦 London, Ontario, Canada

Ottawa Civic Hospital / University of Ottawa Heart Institute; 🇨🇦 Ottawa, Ontario, Canada

St. Michael's Hospital; 🇨🇦 Toronto, Ontario, Canada

Scarborough Cardiology Research; 🇨🇦 Scarborough, Ontario, Canada

Complexe Hospitalier de la Sagamie; 🇨🇦 Chicoutimi, Quebec, Canada

University Health Network; 🇨🇦 Toronto, Ontario, Canada

CSSS-Hopital de Gatineau, secteur Hull; 🇨🇦 Gatineau, Quebec, Canada

Q & T Research; 🇨🇦 Gatineau, Quebec, Canada

Viacar Recherche Clinique; 🇨🇦 Greenfield Park, Quebec, Canada

Montreal Heart Institute; 🇨🇦 Montréal, Quebec, Canada

Foothills Medical Centre; 🇨🇦 Calgary, Canada

CUSM Montreal General Hospital; 🇨🇦 Montréal, Quebec, Canada

CHUM - Hopital Hotel-Dieu; 🇨🇦 Montréal, Quebec, Canada

Hopital Sacré-Cœur de Montreal; 🇨🇦 Montréal, Quebec, Canada

Institut Universitaire de Cardiologie et de Pneumologie de Québec; 🇨🇦 Québec, Quebec, Canada

St-Jerome Medical Research Inc.; 🇨🇦 Saint-Jérôme, Quebec, Canada

Universitat Heidelberg; 🇩🇪 Heidelberg, Germany

Centre de santé et des services sociaux de Beauce; 🇨🇦 Saint-Georges, Quebec, Canada

Centre Hospitalier Régional de Lanaudière; 🇨🇦 Saint-Charles-Borromée, Quebec, Canada

CSSS Vallée de l'Or; 🇨🇦 Val D'Or, Quebec, Canada

Sunnybrook Health Science Center; 🇨🇦 Toronto, Quebec, Canada

Centre de santé et de services sociaux de Trois-Rivières; 🇨🇦 Trois-Rivières, Quebec, Canada

Universitatsklinikum Aachen; 🇩🇪 Aachen, Germany

Royal University Hospital; 🇨🇦 Saskatoon, Saskatchewan, Canada

Klinikum Darmstadt; 🇩🇪 Darmstadt, Germany

Wojewodzki Szpital; 🇵🇱 Elblag, Poland

Universitatsklinikum Ulm; 🇩🇪 Ulm, Germany

Uniwersyteckie Centrum Kliniczne; 🇵🇱 Gdansk, Poland

Oddzial Kliniczny Choroby; 🇵🇱 Krakow, Poland

Samodzielny Publiczny; 🇵🇱 Lublin, Poland

Szpital Kliniczny; 🇵🇱 Poznan, Poland

Instytut Kardiologii; 🇵🇱 Warszawa, Poland

Klinika Kardiologii; 🇵🇱 Warszawa, Poland

Woskowy Szpital Kliniczny; 🇵🇱 Wroclaw, Poland

Hopitaux Universitaire de Genève; 🇨🇭 Geneve, Switzerland

Victoria Heart Institute Foundation (Office)/Royal Jubilee Hospital; 🇨🇦 Victoria, British Columbia, Canada

CDRC Rive Sud; 🇨🇦 Longueuil, Quebec, Canada

CHUS-Hopital Fleurimont; 🇨🇦 Fleurimont, Quebec, Canada

Royal Alexandra Hospital; 🇨🇦 Edmonton, Alberta, Canada

Royal Columbian Hospital; 🇨🇦 New Westminster, British Columbia, Canada

Cite de la Sante; 🇨🇦 Laval, Quebec, Canada

Queen Elizabeth II - Health Sciences Centre; 🇨🇦 Halifax, Nova Scotia, Canada

Vancouver General Hospital; 🇨🇦 Vancouver, British Columbia, Canada

Dalla VAMC; 🇺🇸 Dallas, Texas, United States

Jim Moran Heart and Vascular Research Institute, Holy Cross Hospital; 🇺🇸 Fort Lauderdale, Florida, United States

Florida Cardiovascular Research; 🇺🇸 Tampa, Florida, United States

Norton Heart Specialist Springs; 🇺🇸 Louisville, Kentucky, United States

University of North Carolina Hospital; 🇺🇸 Chapel Hill, North Carolina, United States